RecruitingPhase 4

STunning in Acute Myocardial Infarction - BAS

Sweden120 participantsStarted 2025-01-06

Plain-language summary

The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with STEMI who undergo primary PCI within 6 hours of symptom onset (Excluding prodromal symptoms)
✓. Informed consent

Exclusion criteria

✕. Killip class ≥ 3
✕. Chronic kidney disease with GFR \< 25 ml/min/1.73 m2
✕. Pre-existing non-reversible cardiac dysfunction or heart failure
✕. Current treatment with any beta blocker, RAAS inhibitor or SGLT2 inhibitor
✕. Absolute or relative contraindication to any one of the study drugs that confers a risk of patient safety if the patient participates in the trial and adheres to the protocol-specified recommendations, per the assessment of the treating physician
✕. Life expectancy less than one year
✕. Pregnancy or women of childbearing potential who is not sterilized or is not using a medically accepted form of contraception

What they're measuring

Measurement of Global longitudinal strain (GLS, %)

Timeframe: day 7±24 hours

Trial details

NCT IDNCT06562582

SponsorVastra Gotaland Region

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2027-12-31

Contact for this trial

Björn Redfors, Professor

+46 31342100 bjoern.redfors@wlab.gu.se

View on ClinicalTrials.gov More Myocardial Infarct trials